LUNG CANCER TREATMENT CONSEQUENCES OF THE LACK OF
- Slides: 20
LUNG CANCER TREATMENT CONSEQUENCES OF THE LACK OF PATIENTS OF COLOR & STRUCTURAL BARRIERS TO QUALITY Christopher S. Lathan, M. D. , M. S. , M. P. H. Assistant Professor of Medicine Faculty Director of Cancer Care Equity, Dana-Farber Cancer Institute
Overview Race/SES Disparities in lung cancer Targeted therapy in Lung Cancer Treatment equity
Disparities Framework Kawaga-Singer CA, 2010
Male Death Rates for NSCLC Cancer Facts and Figures for African Americans 2013
NSCLC and Race The incidence rates and mortality rates of lung cancer are highest in Black men Over the past 40 years there has been a decrease in lung cancer incidence and mortality in all races Black men are still more likely to have lung cancer when smoking habits are adjusted for. Cancer Facts and Figures for African Americans 2013
Lung Cancer and Income Low income takes on special importance in lung cancer: Double jeopardy phenomenon Low income increased risk due to tobacco Low income increases risk of dying Income is directly related to stage of disease at presentation Stage at presentation drives mortality Albano et al JNCI 2007
Targeted Therapy for Lung Cancer
Personalized Medicine www. mdanderson. org/. . . /index. html
EGFR Four groups of patients showed increased response to gefitinib (Miller et al. , JCO, 2004). Patients with adenocarcinoma. Patients from Japan (compared to U. S. or Europe) Women Non-smokers Before treatment After 3 months gefitinib treatment Same patient population in whom we found EGFR mutations In Paez, Pao and Lynch reports, 25 of 31 gefitinib responders had EGFR mutations—validated in larger studies Slide courtesy of M. Meyerson MD
EGFR Timeline EGFR mutations identified 2004 1990 s 2005 2009 Quinazoline EGFR inhibitors Gefitinib approved for EGFR discovered mutant NSCLC Erlotinib approved for NSCLC First EML 4 -ALK patient treated with ALK inhibitor Crizotinib approved for 2011 ALK-rearranged NSCLC 2008 ALK Timeline 2007 EML 4 -ALK discovered Courtesy of Pasi Janne MD 2009 Phase III study starts
Evolution of Identification of Genomic Alterations in Lung Adenocarcinoma No known genotype 1984 - 2003 2009 Courtesy of Pasi Janne MD 2004 2013
Benefits of understanding racial differences in mutation frequency EGFR mutations in lung adenocarcinoma are much less common in Caucasian (8%) than East Asian (30%) populations—note that these are racial differences in SOMATIC mutations EGFR mutations are somatic, so racial differences may be due to inherited differences in some other genes, or due to environmental factors (diet, socioeconomic, etc. ) Christopher S. Lathan MD MS MPH
Benefits of understanding racial differences in mutation frequency Frequencies of EGFR mutations in populations of African descent are not well characterized Frequencies of other genomically altered therapeutic targets (BRAF, ALK, ERBB 2) were completely uncharacterized in African-American and African populations. (recent study) Christopher S. Lathan MD MS MPH
Lung cancer Targets Different Human Populations Cancer Gene Caucasians African Americans East Asians *EGFR 10 -20% ~10% 30 -60% KRAS 20 -30% MET C-met 5. 3% ~4. 5% 13. 5% EML 4 -ALK 5. 6 -13% ? 3. 7% Reproduced from Patrick Ma ASCO 2010
Genotype Directed Clinical Trials Gene EGFR ALK KRAS BRAF ERBB 2 PIK 3 CA ROS 1 FGFR RET MET Clinical Trial 09 -210 (Erlotinib); 09 -018 (dacomitinib) 12 -075 (CH 5424802) 12 -547 (selumetinib +/- docetaxel) 11 -023 (GSK 2118436) 09 -018 (dacomitinib); 13 -148 (neratinib +/- temsirolimus) 10 -419 (GDC-0980 & chemo) 06 -068 (phase I Crizotinib) 12 -327 (ponatinib) 13 -086 (sunitinib) 06 -068 (phase I Crizotinib); 11 -484 (Erlotinib +/- Met. Mab)
BATTLE STUDY Kim E S et al. Cancer Discovery 2011; 1: 44 -53
Sequencing Alk and EGFR on all adenocarcinomas Squamous cells per protocol ROS, BRAF, HER 2 PIK 3 CA Secondary Mutations re-biopsy Immune based therapy is changing practice, Nivolumab, Pembrolizumab and PD-L 1 markers are the next frontier. Christopher S. Lathan MD MS MPH
Lynch et al Genet Med 2013 Christopher S. Lathan MD MS MPH
Institutions Adopting EGFR assay H – NCI CC Ordered EGFR Assay Lynch et al Genet Med 2013
Summary Racial/class disparities are multifactorial, and multilevel requiring not only improvements in treatments, but also access resulting in treatment equity. Without a focus on disseminating somatic testing to underserved patients, the technology can exacerbate existing disparities. Community based efforts : are needed to have representative samples across tissue type. Christopher S. Lathan MD MS MPH
- Servier medical art
- Optimal lung cancer pathway
- Tnm staging lung cancer
- Lung cancer screening shared decision making tool
- Lifetime risk of lung cancer
- Diabetes insipidus siadh cerebral salt wasting
- Disturbed thought process nanda
- Gesundheit central european lung cancer patient ne
- Dr. amy ford
- Cancer treatment
- Treatment of inflammatory breast cancer
- Which of the following explains this phenomenon?
- Consequences of bad manners
- Which one is a barrier to speaking
- Users over lack support
- Your child's success or lack of success
- Lack of dopamine
- Vascocongestion
- English 2 honors vocabulary unit 1
- Voluntary consent meaning
- Aden/o medical term